A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients

Completed · Not applicable · Has a placebo group

Conditions studied: End-Stage Renal Disease Patients on Hemodialysis

In brief

The main goal of this study is to determine whether the American Heart Association-recommended fish oil dose is efficacious, safe, and tolerable in hemodialysis patients. The secondary objective is to test the effects of fish oil supplementation on inflammatory and cardiovascular markers.

Key facts

Study ID

NCT00308295

Run by

Indiana University

People needed

27

Starts

2006-04-01

Expected to finish

2006-05-01

Last updated by the study team

2007-10-16

Who can join

Age: 18 and older, up to 82. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Age <18
• Pregnant individuals
• Fish oil or omega-3 supplementation in past 6 months
• Fish, corn, soybean, gelatin, or vanilla allergies
• Currently enrolled in a dietary or investigational drug study
• Life expectancy < 3 months
• Ongoing active illness requiring hospitalization
• Malabsorption syndromes
• Chronic heparin or coumadin anticoagulation (??)
• Active bleeding issues

Where it is running

• Indiana University Nephrology Clinics — Indianapolis, Indiana, United States
• VeteransAdministration Hospital — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.